22 Apr 2020
The Healthcare Analytical Testing Market is expected to reach USD 6690.82 million by 2025 from an estimated USD 4053.99 million in 2025, at a CAGR 11.54%.
Based on end user, the pharmaceutical and biopharmaceutical organizations section represented the biggest portion of the healthcare analytical testing services market. The huge portion of this fragment can be credited to expanding re-appropriating of analytical testing services by pharmaceutical and biopharmaceutical companies to boost profit margins, its keep away from high capital consumption, and reduce the time required to approve the procedure and item, Key discoveries are highlighted in the Healthcare Analytical Testing Services analysis to guide market players to evaluate Healthcare Analytical Testing Services investment feasibility.
The study provides a decisive view of the global Healthcare Analytical Testing market by segmenting the market based on product, animal type and region. Global Healthcare Analytical Testing Services Market, By Type (Bioanalytical Testing, Method Development & Validation, Physical Characterization, Raw Material Testing, Others) By End-User (Contract Research Organizations, Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies)
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 47,000 staff in more than 800 laboratories across 45 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
- Eurofins Testing for Life – Supporting the Fight against Coronavirus:-
Eurofins is Testing for Life. Never is this more true than today, as we put our full energy and commitment towards supporting the fight against this global pandemic. We are a community of people including scientists and entrepreneurs, who are banded together to provide excellence in scientific innovation and service. As the world faces the challenges of COVID-19, at Eurofins we are ever mindful of our vision, and the race to bring all of our resources to bear on the saving of lives during this crisis
LabCorp, headquartered in Burlington, North Carolina, is a leading global life sciences company that is deeply integrated in guiding patient care through its comprehensive clinical laboratory and end-to-end drug development services. Employing nearly 65,000 employees worldwide, the company’s mission is to improve health and improve lives by delivering world-class diagnostics, accelerating the availability of innovative medicines to patients, and using technology to change the way care is delivered. LabCorp serves a broad range of customers, including managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories.
- LabCorp Launches Test for Coronavirus Disease 2019 (COVID-19)
- LabCorp Developing Options to Prioritize COVID-19 Testing for Inpatient Population in Support of Guidance from the White House Coronavirus Task Force
SGS is the world’s leading inspection, verification, testing and certification company. We are recognized as the global benchmark for quality and integrity. With more than 94,000 employees, we operate a network of more than 2,600 offices and laboratories around the world. We are constantly looking beyond customers’ and society’s expectations in order to deliver market leading services wherever they are needed. As the leader in providing specialized business solutions that improve quality, safety and productivity and reduce risk, we help customers navigate an increasingly regulated world. Our independent services add significant value to our customers’ operations and ensure business sustainability.
For more than 70 years, we have seen technologies advance and new diseases emerge. Our one-man laboratory has evolved into a worldwide support network, allowing us to act as a steadfast partner to our clients, from discovery to lot release testing. By carefully cultivating our portfolio, our growth has become a continuous strategic effort in anticipating tomorrow’s drug development needs. While we can’t predict what the future holds, we continue to kindle the spark that inspired our founding: an urgency to advance human health by supporting our clients’ research every step of the way.
Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated"
Pharmaceutical Product Development
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.
The combined company, which is majority owned by Bridgepoint, an international private equity firm, now has more than 6,200 employees and will operate in the future as Element Materials Technology. The new Element Group will consist of 200 laboratories located in more than 30 countries. This latest acquisition by Element follows a period of significant growth for the business, helping it to become the fastest growing independent materials testing and product qualification company in the world. It is expected that the combined group will deliver in excess of $700m in annual revenues and serve more than 40,000 customers worldwide. Element will continue under the leadership of CEO and President Charles Noall, alongside an Executive Team formed from senior management from both companies.
We have continuously improved and today we continue to live our vision of delivering science better. We promise to provide the highest quality testing and scientific services in the industry, supported by ethical standards, transparency, and personalized support
Envigo provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia and other life science organizations. As the largest organization that is solely dedicated to providing research models and related products and services, we are committed to helping researchers realize the full potential of their critical R&D projects as we fulfill our mission to work together to build a healthier and safer world.
For more than 130 years, Intertek’s story has always been about innovation. In 1885 we began testing and certifying grain cargoes before they were put to sea, and in 1888 we pioneered the idea of independent testing laboratories. Then in 1896, the greatest inventor of them all became part of our story. When Thomas Edison released the wonders of electricity and the light bulb he wanted to ensure that his products were checked, tested and safe. He established the Lamp Testing Bureau, later to become the Electrical Testing Laboratories. Over a century later, we maintain his ETL mark of quality, and continue to establish new standards in quality to protect consumers and our clients’ reputations across the world. Today we are a global force, operating in over 100 countries, offering Total Quality Assurance expertise, delivered consistently with precision, pace and passion, enabling our customers to power ahead safely.